S Litvinjenko1, D Lunny2. 1. Formerly at the Northwestern Health Unit, Kenora, ON. 2. Northwestern Health Unit, Kenora, ON.
Abstract
BACKGROUND: Blastomycosis, caused by the organism Blastomyces dermatitidis, is an invasive fungal disease found in Central Canada and Central and Midwestern United States. OBJECTIVE: To describe trends in and epidemiology of hospitalized cases of blastomycosis cases reported among northwestern Ontario residents between 2006 and 2015. METHODS: Blastomycosis hospitalization data were extracted from the Discharge Abstract Database (DAD), accessed through IntelliHEALTH Ontario. The DAD includes administrative, clinical and demographic information on hospital discharges provided by the Canadian Institute for Health Information (CIHI). Blastomycosis records were identified using ICD-10 codes B40.0 to B40.9. Hospitalization rates were calculated for all of Ontario, and age-specific hospitalization rates were calculated for northwestern Ontario and analyzed by local health region, time and seasonality as well as presenting symptoms. RESULTS: There were 581 hospitalizations for blastomycosis reported in Ontario over this 10-year period. Of these, 245 (42%) were from northwestern Ontario, although this region accounts for only 0.6% of the Ontario population. The average hospitalization rate for blastomycosis in northwestern Ontario was 35.0 per 100,000 per year. This rate varied from 1.7 in the Red Lake region to 57.9 in the Kenora region. The most common presentation was acute pulmonary symptoms. Men were 1.36 times more likely to be hospitalized for blastomycosis than were women (95% confidence interval [CI]: 1.06-1.75, P<0.05). Most hospitalizations were registered in the late fall months, suggesting blastomycosis exposure in the spring/summer season followed by a lengthy incubation period. CONCLUSION: Areas of northwestern Ontario have high reported rates of blastomycosis. It is not known to what extent there are regional differences in other states and provinces. Interregional differences may warrant prioritizing strategies for blastomycosis prevention and control as well as additional research and surveillance.
BACKGROUND: Blastomycosis, caused by the organism Blastomyces dermatitidis, is an invasive fungal disease found in Central Canada and Central and Midwestern United States. OBJECTIVE: To describe trends in and epidemiology of hospitalized cases of blastomycosis cases reported among northwestern Ontario residents between 2006 and 2015. METHODS: Blastomycosis hospitalization data were extracted from the Discharge Abstract Database (DAD), accessed through IntelliHEALTH Ontario. The DAD includes administrative, clinical and demographic information on hospital discharges provided by the Canadian Institute for Health Information (CIHI). Blastomycosis records were identified using ICD-10 codes B40.0 to B40.9. Hospitalization rates were calculated for all of Ontario, and age-specific hospitalization rates were calculated for northwestern Ontario and analyzed by local health region, time and seasonality as well as presenting symptoms. RESULTS: There were 581 hospitalizations for blastomycosis reported in Ontario over this 10-year period. Of these, 245 (42%) were from northwestern Ontario, although this region accounts for only 0.6% of the Ontario population. The average hospitalization rate for blastomycosis in northwestern Ontario was 35.0 per 100,000 per year. This rate varied from 1.7 in the Red Lake region to 57.9 in the Kenora region. The most common presentation was acute pulmonary symptoms. Men were 1.36 times more likely to be hospitalized for blastomycosis than were women (95% confidence interval [CI]: 1.06-1.75, P<0.05). Most hospitalizations were registered in the late fall months, suggesting blastomycosis exposure in the spring/summer season followed by a lengthy incubation period. CONCLUSION: Areas of northwestern Ontario have high reported rates of blastomycosis. It is not known to what extent there are regional differences in other states and provinces. Interregional differences may warrant prioritizing strategies for blastomycosis prevention and control as well as additional research and surveillance.
Authors: Tracy L Crampton; R Bruce Light; Greg M Berg; Michael P Meyers; Gary C Schroeder; Earl S Hershfield; John M Embil Journal: Clin Infect Dis Date: 2002-04-22 Impact factor: 9.079
Authors: B S Klein; J M Vergeront; R J Weeks; U N Kumar; G Mathai; B Varkey; L Kaufman; R W Bradsher; J F Stoebig; J P Davis Journal: N Engl J Med Date: 1986-02-27 Impact factor: 91.245
Authors: Stanley W Chapman; William E Dismukes; Laurie A Proia; Robert W Bradsher; Peter G Pappas; Michael G Threlkeld; Carol A Kauffman Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Shaun K Morris; Jason Brophy; Susan E Richardson; Richard Summerbell; Patricia C Parkin; Frances Jamieson; Bill Limerick; Lyle Wiebe; E Lee Ford-Jones Journal: Emerg Infect Dis Date: 2006-02 Impact factor: 6.883
Authors: Elizabeth M Brown; Lisa R McTaggart; Deirdre Dunn; Elizabeth Pszczolko; Kar George Tsui; Shaun K Morris; Derek Stephens; Julianne V Kus; Susan E Richardson Journal: Emerg Infect Dis Date: 2018-07 Impact factor: 6.883
Authors: Nida Ashraf; Ryan C Kubat; Victoria Poplin; Antoine A Adenis; David W Denning; Laura Wright; Orion McCotter; Ilan S Schwartz; Brendan R Jackson; Tom Chiller; Nathan C Bahr Journal: Mycopathologia Date: 2020-02-10 Impact factor: 2.574